InvestmentJun 18, 2026, 08:07 AM
RedHill Biopharma Announces Up To $19.4M Private Placement
AI Summary
RedHill Biopharma Ltd. announced a private placement to raise up to $19.4 million. The company expects to receive approximately $6 million upfront from the sale of American Depositary Shares (ADSs) and accompanying warrants, with an additional potential $13.4 million if the Series A-1 and Series A-2 warrants are fully exercised. The proceeds are intended to support a potential strategic product acquisition, working capital, research and development, and general corporate purposes.
Key Highlights
- RedHill Biopharma announced a private placement to raise up to $19.4 million.
- Expected gross proceeds of approximately $6 million upfront from the offering.
- Potential additional gross proceeds of $13.4 million if warrants are fully exercised.
- Proceeds will support a potential strategic product acquisition, working capital, and R&D.
- The placement includes 8,571,429 ADSs and Series A-1 and A-2 warrants.
- Series A-1 warrants have an exercise price of $0.86 per ADS and Series A-2 warrants at $0.70 per ADS.
- The private placement is expected to close on June 22, 2026.
Price Impact
More from RDHL